NCT02137889终止1 期
A Phase 1, Muticenter, Open-label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 When Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Dose limiting toxicities (DLTs)
研究概览
简要总结
This study will assess the safety and preliminary efficacy of escalating doses of VAY736 in relapsed or refractory CLL patients.
详细描述
This Phase 1, multicenter, open-label, study will investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary antil-CLL activity of VAY736 in patients with relapsed/refractory CLL who have received at least two prior regimens. The study will include one arm in the dose escalation phase and two arms in the dose expansion phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose escalation: Relapsed/refractory CLL following at least -two prior treatment regimen
- •Dose expansion:
- •Arm 1: Relapsed/refractory CLL following two to three prior treatment regimens
- •Arm 2: Relapsed/refractory CLL following four or more prior treatment regimens
- •Discontinued any previous anti-cancer and investigational therapy including radiation, radioimmunotherapy, and monoclonal antibody therapy for at least 28 days or 5 half-lives of the investigational product, whichever is longer, before study treatment administration, and must have recovered fully from the adverse effects of such treatment before beginning study treatment
- •Discontinued prior alemtuzumab therapy for at least 6 months
- •Age 18 years
- •Eastern cooperative oncology group (ECOG) performance status grade ≤ 1
- •Life expectancy > 3 months
- •Meet the following laboratory criteria (must be obtained within 14 days of enrollment):
- •Adequate end-organ function as assessed by laboratory tests, as specified in the protocol.
- •Written informed consent obtained prior to any screening procedures
排除标准
- •Major surgery within 28 days before study treatment or have not recovered fully from the adverse effects of any major or minor surgical procedures before study treatment
- •History of another primary malignancy that is currently clinically significant or currently requires active intervention (except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that has not been treated in the prior 3 months or expected to require treatment for recurrence during the course of the study).
- •Prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration
- •Clinically significant central nervous system disease
- •Myocardial infarction within 6 months prior to enrollment or New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the investigator
- •History of an active infection requiring systemic therapy within 14 days before study treatment. Prophylactic antibiotics and antiviral therapies are permitted.
- •Active autoimmune disease requiring immunosuppressive therapy
- •Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus or hepatitis B virus or any active bacterial, viral, or fungal infection requiring systemic therapy
- •Ongoing corticosteroid use (>10 mg/day prednisone or equivalent)
- •Pregnant or nursing (lactating) women.
- •Sexually active males must use a condom during intercourse while taking the drug and for 3 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
研究组 & 干预措施
Arm 1- relapsed/refractory CLL patients
Experimental
Patients with relapsed/refractory CLL with two or three prior treatment regimens
干预措施: VAY736 (Drug)
Arm 2 - rituximab or ofatumumab refractory CLL patients
Experimental
Patients with relapsed/refractory CLL with four or more prior treatment regimens
干预措施: VAY736 (Drug)
结局指标
主要结局
Dose limiting toxicities (DLTs)
时间窗: 8 months
Frequency and characteristics of DLTs. Determination of the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of VAY736 when administered weekly in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) (dose escalation only).
次要结局
- VAY736 plasma concentrations(1 year)
- Blood Serum concentrations of antibodies to VAY736(1 year)
- Hematology parameters of VAY736(1 year)
- Number of patients with Advers Events (AEs) as a measure of safety and tolerability.(1 year)
- PharmacoKinetics (PK) parameters of VAY736(1 year)
- Receptor occupancy for VAY736(1 year)
- Overall response rate (ORR)(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)NCT03625505AbbVie61
已完成
1 期
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United StatesSARS-CoVSARS-CoV-2NCT05870839Vaccine Company, Inc.121
已完成
1 期
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsSolid TumorNCT05735366Chugai Pharmaceutical22
进行中（未招募）
1 期
A Phase 1 Study of BB3008 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06143007Broadenbio Ltd., Co.42
已完成
1 期
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South AfricaSARS-CoVSARS-CoV-2NCT05938075Vaccine Company, Inc.130